Insider · CIK 0001730866
Lesley Ann Calhoun
officerdirector
Files at ALGS (Aligos Therapeutics, Inc.), TNGX (Tango Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 9, 2026 | ALGS Aligos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,485 | $0.00 | $0 | 37,485 | Mar 11, 2026 |
| Jul 16, 2025 | ALGS Aligos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +40,185 | $0.00 | $0 | 40,185 | Jul 18, 2025 |
| Jun 5, 2025 | TNGX Tango Therapeutics, Inc. | AGrant or award Common Stock | +6,250 | $0.00 | $0 | 12,500 | Jun 9, 2025 |
| Jun 5, 2025 | TNGX Tango Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +37,500 | $0.00 | $0 | 37,500 | Jun 9, 2025 |
| Feb 28, 2025 | ALGS Aligos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +47,271 | $0.00 | $0 | 47,271 | Mar 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.